|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GLPG1690 decreased irradiation-induced C-C motif chemokine ligand-11 in tumors and levels of interleukin-9, interleukin-12p40, macrophage colony-stimulating factor and interferon γ in adipose tissue adjacent to the tumor.
|
31548293 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The patient underwent trans-sphenoidal tumor resection and repair of skull base for CSF leak with nasoseptal flap placement.
|
31376705 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combination therapy of vaccine microparticles with cyclophosphamide and granulocyte macrophage-colony stimulating factor (GM-CSF) demonstrated a five-fold reduction in tumor volume as compared to non-vaccinated mice.
|
31477437 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumor bearing mice vaccinated with a GMCSF-expressing CT-26 GVAX vaccine had reduced tumor growth when given IL2-R336A before vaccination.
|
31059598 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previously, our group has shown that a GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) may prime the tumor microenvironment by inducing intratumoral T cell infiltration.
|
30747725 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
For patients with ePFTs, petroclival/midline tumor location (OR 12.2/OR 5.7), perilesional edema (OR 10.0), and preoperative hydrocephalus (OR 4.0) were independent predictors of need for CSF drainage.
|
30611134 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ex vivo results showed that the tumor inhibition efficacy of delNS1-GM-CSF was observed in HCC clinical samples.
|
30205709 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we used mJX-594 (JX), a targeted and GM-CSF-armed oncolytic vaccinia virus, as a strategy to remodel the tumor microenvironment (TME) and subsequently increase sensitivity to αPD-1 and/or αCTLA-4 immunotherapy.
|
30538109 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PCNSL is a highly invasive tumour.With the development of technologies such as cerebrospinal fluid cytology and flow cytology, CSF analysis has become one of the definite diagnosis methods, and the tumour cell finding in CSF is the only reliable basis for diagnosis.
|
31064334 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Higher protein expression of inflammatory cytokines and growth factors such as epidermal growth factor, granulocyte-macrophage colony-stimulating factor, interferon-α, and interleukin (IL)-8 was observed in the tumour and serum of cachectic cancer patients in comparison with weight-stable counterparts.
|
31273954 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this article, the incidence, risk factors and complications of CSF leaks after spine tumor surgery are reviewed, with an emphasis on avoidance of post-operative CSF leaks, early post-operative identification and effective secondary intervention.
|
31297382 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Irradiated Bladder Cancer Cells Expressing both GM-CSF and IL-21 versus Either GM-CSF or IL-21 Alone as Tumor Vaccine in a Mouse Xenograft Model.
|
31467912 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A systemic stimulation of macrophages by rhGM-CSF resulted in significantly reduced and delayed tumor growth in the rodent C6 glioma model.
|
31186691 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The activated HIF-1α can up-regulate GM-CSF expression and secretion, which promoted the migration of Schwann cells in tumor microenvironment.
|
30922919 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the current study, a bicistronic adenoviral vector, Ad-CD-GMCSF, carrying the cytosine deaminase (CD) and granulocyte-macrophage colony-stimulating factor (GM-CSF) transcription units driven by a cytomegalovirus promoter was constructed, and the <i>in vitro</i> efficacy of the vector was tested in tumor cell lines and a syngeneic mouse model of colon cancer.
|
30892086 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.
|
31620131 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CONCLUSIONS Preoperative BMI > 25 kg/m<sup>2</sup> and tumor location in the posterior fossa were associated with higher rates of postoperative CSF leak.
|
28598276 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A positive correlation between GM-CSF and IL6 expression and disease course was observed by meta-analyses of the clinical data.<b>Conclusions:</b> Our studies indicate a significant reappraisal of the role of IL6 and GM-CSF in metastasis and implicate CAFs as the "henchmen" for cancer cells in producing an immunosuppressive tumor ecological niche.
|
29959142 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we evaluated safety and immunogenicity of Apo-DC in combination with lenalidomide, granulocyte-macrophage colony-stimulating factor (GM-CSF), and low-dose cyclophosphamide (CTX).
|
29569742 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We build the latent membrane protein gene latent membrane protein 2A (LMP2A) and the granulocyte-macrophase colony-stimulating factor (GM-CSF) gene fusion gene (CSF2A) and discuss how the CSF2A fusion protein influenced the proliferation and apoptosis of Epstein-Barr virus-positive (EBV<sup>+</sup> ) tumor cells.
|
29900557 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chemiluminescent enzyme immunoassay was utilized to measure CSF PLAP in the following tumor sites: pineal (n = 32), pituitary stalk, suprasellar (n = 16), basal ganglia (n = 15), intraventricular (n = 9), and cerebellar (n = 5) regions.
|
30265190 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeted cancer immunotherapy with irradiated, granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting, allogeneic cancer cell lines has been an effective approach to reduce tumor burden in several patients.
|
29867922 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anchored-GM-CSF vaccine combined with anti-PD-1 antibody could effectively inhibit tumor growth and even cause regression of the established tumor.
|
30519342 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The purpose of the present investigation was to study the GM-CSF gene therapy effects in regression of tumor masses in fibrosarcoma mouse model.
|
28643761 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated whether the CSF cleft sign on ADC maps is beneficial for differentiating extra-axial tumors from intra-axial tumors.
|
28623761 |
2018 |